^
Association details:
| Biomarker: | BRCA2 I2315T |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | Lynparza (olaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A novel somatic BRCA2 point mutation in a metastatic pancreatic cancer patient: a case report
Published date:
01/06/2021
Excerpt:
Due to the novel nonsynonymous BRCA2 point mutation, we decided to change the strategy by administering olaparib. The patient benefited from olaparib therapy and achieved a PFS of ~ 6.5 months....We describe a patient carrying a novel somatic BRCA2 p. I2315T point mutation, which is first reported in metastatic pancreatic cancer.
DOI:
10.1186/s12920-020-00850-6
